Last Price$2.52Cboe Real-Time Last Sale as of 9:57AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(3.64%)
Bid (Size)$2.51 (105)
Ask (Size)$2.52 (383)
Day Low / High$2.53 - 2.62
Volume62.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/27/2022


Omeros Corp ( NASDAQ )

Price: $2.52
Change: -0.09 (3.64%)
Volume: 62.4 K
9:57AM ET 6/27/2022

Sesen Bio Inc ( NASDAQ )

Price: $0.78
Change: -0.04 (4.72%)
Volume: 217.2 K
9:55AM ET 6/27/2022

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $0.85
Change: -0.03 (3.41%)
Volume: 207.5 K
9:57AM ET 6/27/2022

Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.81
Change: +0.005 (0.63%)
Volume: 13.4 K
9:54AM ET 6/27/2022

Savara Inc ( NASDAQ )

Price: $1.59
Change: +0.02 (1.27%)
Volume: 8.4 K
4:00PM ET 6/24/2022

Read more news Recent News

Omeros Shares Fall After BofA Downgrade
12:59PM ET 6/08/2022 MT Newswires

Omeros (OMER) shares are down nearly 11% in early afternoon trading after the biopharmaceutical company's stock was downgraded by BofA Securities. The firm...

--BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target
9:32AM ET 6/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Omeros Says Results of Study Evaluating Narsoplimab Published in Journal of Clinical Oncology
11:49AM ET 4/20/2022 MT Newswires

Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...

Omeros Q4 Adjusted Loss Widens in Wake of Omidria Sale
5:21PM ET 3/01/2022 MT Newswires

Omeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...

Company Profile

Business DescriptionOmeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA. View company web site for more details
AddressThe Omeros Building
Seattle, Washington 98119
Phone+1 206 676-5000
Number of Employees236
Recent SEC Filing06/24/20228-K
Chairman, President & Chief Executive OfficerGregory A. Demopulos
Chief Financial Officer, Treasurer & VPMichael A. Jacobsen
Chief Scientific Officer & Vice President-ScienceGeorge A. Gaitanaris
Chief Medical Officer & Vice PresidentJ. Steven Whitaker

Company Highlights

Price Open$2.62
Previous Close$2.61
52 Week Range$1.86 - 16.57
Market Capitalization$157.8 M
Shares Outstanding62.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings0.83
Earnings per Share-$1.75
Beta vs. S&P 500N/A
Revenue$29.9 M
Net Profit Margin-234.76%
Return on Equity112.70%

Analyst Ratings as of 06/08/2022

Consensus RecommendationConsensus Icon
Powered by Factset